Facebook Instagram Tiktok Yelp Youtube
Begin Your Journey
Book Now

PT-141

Supporting Desire, Confidence, and Connection

Sexual health is a meaningful part of overall well-being — and changes in desire can be frustrating, confusing, and often misunderstood.
At Radiant You, we take a thoughtful, evidence-based approach to intimacy and sexual wellness, helping you understand what’s happening in your body and what options may help.
Begin Your Journey

Why We’re Providing You This Information

At Radiant You, we believe you deserve to understand the complete scientific evidence behind every recommended intervention so that you can make the best decision for your health. This overview explains what PT-141 is, how it works, and what you can realistically expect from treatment.
Begin Your Journey

What Is PT-141?

Bremelanotide (PT-141) is a peptide medication approved for the treatment of:
  • Acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal
    women
HSDD is defined as:
  • Low sexual desire
  • Causing personal distress
  • Not explained by a medical condition, medication, relationship factors, or another. diagnosis
How It Works
PT-141 works differently than hormone therapy.
  • It does not increase estrogen or testosterone
  • It acts in the brain on melanocortin receptors involved in sexual desire
In simple terms:
  • It works on the neural pathways of desire, rather than hormone levels.

How It’s Used

  • Dose: 1.75 mg
  • Route: Subcutaneous injection
  • Timing: ~45 minutes before anticipated activity
Maximum use:
  • No more than once in 24 hours
  • No more than 8 times per month
If there is no meaningful benefit after ~8 weeks, we reassess and typically discontinue.

What the Research Shows

PT-141 was studied in large Phase 3 trials involving over 1,200 women with HSDD.
Compared to placebo, patients experienced:
  • Statistically significant increases in sexual desire
  • Reduction in distress related to low desire
Important context:
  • The degree of improvement is moderate, not dramatic
  • Not all patients respond
  • Placebo response is common in sexual health research

What It May Help With

PT-141 may support:
  • Increased sexual desire
  • Reduced distress related to low libido
  • Improved subjective sexual satisfaction
It does not treat:
  • Hormone deficiencies
  • Vaginal dryness
  • Relationship dynamics
  • Psychological or emotional contributors
For many patients, it works best as part of a broader, personalized plan.
Blood Pressure Effects
PT-141 may cause temporary:
  • Increase in blood pressure (~5–6 mmHg)
  • Decrease in heart rate
These effects typically resolve within 12 hours.
It is not recommended for patients with:
  • Uncontrolled hypertension
  • Significant cardiovascular disease

Common Side Effects

Side effects are relatively common but usually mild to moderate.
  • Nausea: up to ~40% (most common, often improves with time)
  • Flushing: ~20%
  • Headache: ~10–11%
  • Injection site reactions: ~10–15%
About 18% of patients discontinued treatment in clinical trials due to side effects.
Begin Your Journey

Skin Pigmentation Changes

A small number of patients (~1%) may develop. This primarily was seen in patients taking higher doses than recommended by Radiant You:
  • Darkening of the skin (face, gums, or breasts)
Risk appears higher with:
  • Frequent dosing
  • Darker skin tones
In some cases, pigmentation may persist.

How This Fits Into Your Care

At Radiant You, we don’t view sexual health as a single-treatment issue.
PT-141 is considered when:
  • HSDD is clearly identified
  • Hormonal contributors have been evaluated
  • Expectations are realistic
  • Safety has been assessed
It is not a universal solution — but for some patients, it can meaningfully improve desire and reduce distress.
Begin Your Journey

Our Approach to Intimacy

We take a comprehensive, personalized approach that usually includes:
  • Hormonal optimization (when appropriate)
  • PRP-based therapies (O-shot)
  • Lifestyle and metabolic health support
  • Education and expectation-setting
Our goal is not just symptom improvement — but helping you feel more connected, confident, and supported.

The Bottom Line

PT-141 is a brain-based therapy designed to support sexual desire in women with HSDD.
  • It can improve desire and reduce distress
  • Benefits vary from person to person
  • Side effects are common but often manageable
If it helps, we continue. If it doesn’t, we reassess together.

Sources & Further Reading

Mechanism of Action

  • Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019.
  • Pfaus JG et al. The Neurobiology of Bremelanotide. CNS Spectrums. 2022.

Phase 3 Clinical Trials (RECONNECT)

  • Kingsberg SA et al. Bremelanotide for HSDD: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019.
  • Simon JA et al. Subgroup Analyses from RECONNECT Trials. Journal of Women’s Health. 2022.

Long-Term Safety

  • Simon JA et al. 52-Week Safety & Efficacy Data. Obstetrics & Gynecology. 2019.
  • Clayton AH et al. Safety Across Clinical Development Program. Journal of Women’s Health. 2022.

Clinical Perspective

  • Cipriani S et al. Evaluation of Bremelanotide for HSDD. Expert Opinion on
    Pharmacotherapy. 2023.
  • Davis SR. Sexual Dysfunction in Women. New England Journal of Medicine. 2024.
  • Dalrymple SN et al. Female Sexual Dysfunction. American Family Physician. 2025.
Instagram Facebook